Video

Dr. Martin on Potential Drug-Drug Interactions With BTK Inhibitors in MCL

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Peter Martin, MD, chief, the Lymphoma Program, Meyer Cancer Center, associate professor of medicine, Weill Cornell Medicine, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma (MCL).

Currently, 3 BTK inhibitors, ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa), are approved to treat patients with relapsed/refractory MCL. However, without comparative data, selecting between these agents is challenging. As such, understanding potential drug-drug interactions with BTK inhibitors may inform treatment selection. For example, acalabrutinib is absorbed less efficiently in patients also receiving gastric acid–reducing agents, including proton pump inhibitors or H2 blockers, such as famotidine (Pepcid AC), says Martin. Moreover, as many patients with MCL remain on gastric acid–reducing agents for a prolonged period of time, this can become a clinically relevant interaction, Martin explains.

Additionally, azoles, which are often utilized to treat or prevent fungal infections that can occur in patients with heavily pretreated lymphomas, could interact with BTK inhibitors, says Martin. Moreover, patients receiving BTK inhibitors in combination with steroids are at an increased risk of developing fungal infections, concludes Martin.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity